US 11,807,682 B2
M971 chimeric antigen receptors
Rimas J. Orentas, Washington, DC (US); Ira H. Pastan, Chevy Chase, MD (US); Dimiter S. Dimitrov, Frederick, MD (US); and Crystal L. Mackall, Stanford, CA (US)
Assigned to The United States of America, as represented by the Secretary, Department of Heath and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on May 8, 2020, as Appl. No. 16/869,792.
Application 16/869,792 is a division of application No. 16/107,271, filed on Aug. 21, 2018, granted, now 10,703,816.
Application 16/107,271 is a division of application No. 14/437,889, granted, now 10,072,078, issued on Sep. 11, 2018, previously published as PCT/US2013/060332, filed on Sep. 18, 2013.
Claims priority of provisional application 61/717,960, filed on Oct. 24, 2012.
Prior Publication US 2020/0283522 A1, Sep. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); A61K 39/00 (2006.01); C12N 15/85 (2006.01); C12N 15/63 (2006.01); C12N 15/64 (2006.01); C12N 15/70 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/0011 (2013.01); C07K 16/3061 (2013.01); C12N 5/0638 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 5/0636 (2013.01); C12N 15/62 (2013.01); C12N 15/625 (2013.01); C12N 15/63 (2013.01); C12N 15/64 (2013.01); C12N 15/70 (2013.01); C12N 15/85 (2013.01); C12N 2501/505 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01)] 26 Claims
 
1. A method of treating a hematological cancer that expresses CD22 in a human, the method comprising administering to the human an effective amount of a chimeric antigen receptor (CAR) T cell to treat the hematological cancer that expresses CD22 in the human; wherein the CAR comprises (a) an antigen binding domain of an antibody which binds to CD22, (b) a transmembrane domain, and (c) an intracellular T cell signaling domain,
wherein the antigen binding domain comprises an amino acid sequence comprising a heavy chain CDR1 comprising SEQ ID NO: 1, a heavy chain CDR2 comprising SEQ ID NO: 2, a heavy chain CDR3 comprising SEQ ID NO: 3, a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6, and
wherein the CAR is the sole CAR expressed by the T cell.